<DOC>
	<DOCNO>NCT01084005</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability linagliptin ( 5 mg / daily ) compare placebo give 24 week add-on therapy stable treatment elderly patient T2DM insufficient glycaemic control</brief_summary>
	<brief_title>Efficacy Safety Linagliptin Elderly Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Type 2 diabetes mellitus 2 . HbA1c &gt; = 7.0 % 3 . Age &gt; = 70 year 4 . Signed date write informed consent Exclusion criterion : 1 . Myocardial infarction , stroke TIA within 3 month prior inform consent 2 . Impaired hepatic function 3 . Treatment glitazones , GLP1 analogues , DPP4 inhibitor rapid act premixed insulins 4 . Treatment antiobesity drug</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>